Skip to main content
SpringerLink
Log in

Bromocriptine treatment of macroprolactinomas: studies on the time course of tumor shrinkage and morphology

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The effects of Bromocriptine (Brc) (7.5 2 - 15 mg/day for 45 days) on serum PRL levels and tumor size and morphology were investigated in 7 patients with macroprolactinomas (mean PRL ± SE = 4957 ± 920 ng/ml). Serial controls of serum PRL levels, CAT scan and visual field examination were carried out at the 5th, 10th, 20th and 45th day of Brc treatment. A rapid lowering in PRL concentrations (mean PRL ± SE = 23.1 ± 5.8 ng/ml) and a dramatic shrinkage of tumor mass were observed in 4 cases already at the 5th day of therapy. In 3 patients Brc was then withdrawn and a rapid rise of serum PRL concentration (mean PRL ± SE = 2618 ± 683 ng/ml) along with a reexpansion of the adenomas was documented within 15 days. These patients were then restarted on Brc and tumor regression was noticed again. In the remaining 3 cases no CAT scan variations occurred, though 2 of them had serum PRL in the normal range. Transsphenoidal adenomectomy was then performed in 4 patients upon Brc (1 with a marked reduction of the adenoma size and 3 with unmodified tumor mass) and tumor tissue examined. The histological picture of the 4 Brc-treated tumors was homogeneous and no relevant changes were seen in comparison with fragments of prolactinomas obtained from patients never treated with Brc. Though PRL cells appeared somewhat more closely associated, neither the tissue architecture, not the distribution of necrotic and hemorragic areas, nor the mitosis rate appeared modified by the treatment. At electron microscopy all the Brc-treated adenomas showed an increase of PRL secretory granules and a decrease of RER and Golgi apparatus. The morphometric analysis revealed in all cases a marked reduction of the cell size in comparison with the untreated tumors (73.56 μm2 ± 6.90 SE vs 148.41 μm2 ± 11.29 SE in untreated patients; p < 0.0001). In conclusion: i) the prolactinoma regression induced by Brc occurred only in patients whose serum PRL levels were markedly suppressed; however the PRL normalization was not constantly associated with tumor shrinkage; ii) all the Brc-treated adenomas showed a marked reduction in cell size and a decrease of the cytoplasmic structures responsible for PRL production; iii) cell size reduction was observed also in 3 patients who did not reduce their tumor size. This suggests that additional mechanisms should have been operating in the Brc-induced tumor shrinkage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Del Pozo E., Varga L., Wyss H., Tolis G., Friesen H., Wenner R., Vetter L., Vettwiler A. Clinical and hormonal response to bromocriptine (CB 154) in te galactorrhoea syndromes. J. Clin. Endocrinol. Metab. 39: 18, 1974.

    Article  PubMed  Google Scholar 

  2. Franks S., Jacobs H.S., Hull M.G.R., Steele S.J., Nabarro J.D.N. Management of hyperprolactinemic amenorrhea. Br. J. Obstet. Gynaecol. 84: 241, 1977.

    Article  PubMed  CAS  Google Scholar 

  3. Bergh T., Nillius S.J., Wide L. Bromocriptine treatment of 42 hyperprolactinemic women with secondary amenorrhea. Acta Endocrinol. (Kbh.) 88: 435, 1978.

    CAS  Google Scholar 

  4. Von Werder K., Fahlbusch R., Landgrat R., Pickardt C.R., Rjosk H.K., Scriba P.C. Treatment of patients with prolactinomas. J. Endocrinol. Invest. 1: 47, 1978.

    Article  PubMed  CAS  Google Scholar 

  5. Thorner M.O., Besser G.M. Bromocriptine treatment of hyperprolactinemic hypogonadism. Acta Endocrinol. (Kbh.) 88 (Suppl. 216): 131, 1978.

    Google Scholar 

  6. Corenblum B. Bromocriptine in pituitary tumors. Lancet 2: 786, 1978.

    Article  PubMed  CAS  Google Scholar 

  7. Wass J.A.H., Moult P.J.A., Thorner M.O., Dacie J.E., Charlesworth M., Jones A.E., Besser G.M. Reduction of pituitary-tumor size in patients with prolactinomas and acromegaly treated with bromocriptine with ot without radiotherapy. Lancet 2: 66, 1979.

    Article  PubMed  CAS  Google Scholar 

  8. McGregor A.M., Scanlon M.F., Hall R., Hall K. Effects of bromocriptine on pituitary tumor size. Br. Med. J. 2: 700, 1979.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  9. Landolt A.M., Wutrick R., Fellmann H. Regression of pituitary prolactinoma after treatment with bromocriptine. Lancet 1: 1082, 1979.

    Article  PubMed  CAS  Google Scholar 

  10. Thorner M.O., Martin W.H., Rogol A.D., Morris J.L., Perryman R.L., Conway B.P., Howards S.S., Wolfman M.G., MacLeod R.M. Rapid regression on pituitary prolactinomas during bromocriptine treatment. J. Clin. Endocrinol. Metab. 51: 438, 1980.

    Article  PubMed  CAS  Google Scholar 

  11. Chiodini P., Liuzzi A., Cozzi R., Verde G., Oppizzi G., Dallabonzana D., Spelta B., Silvestrini F., Borghi G., Lucarelli G., Rainer E., Horowsky R. Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. J. Clin. Endocrinol. Metab. 53: 737, 1981.

    Article  PubMed  CAS  Google Scholar 

  12. Sobrinho L.G., Nunes M.C., Calhaz-Jorge C., Mauricio J.C., Santos A.M. Effect of treatment with bromocriptine on the size and activity of prolactin producing pituitary tumors. Acta Endocrinol. (Kbh.) 96: 24, 1981.

    CAS  Google Scholar 

  13. Wass J.A.H., Williams J., Charlesworth M., Kingsley D.P.E., Halliday A.M., Doniach I., Rees L.H., McDonald W.I., Besser G.M. Bromocriptine in management of large pituitary tumors. Br. Med. J. 284:1908, 1982.

    Article  CAS  Google Scholar 

  14. Corenblum B., Webster B.R., Mortimer C.B. Possible anti-tumor effect of 2-bromo-ergocryptine in two patients with large prolactin-secreting pituitary adenomas. Clin. Res. 23: 614, 1975 (Abstract).

    Google Scholar 

  15. Vaidya R.A., Aloorkar S.D., Rege N.R., Maskati B.T., Jahangir R.P., Sheth A.R., Pandya S.K. Normalization of visual fields following bromocriptine treatment in hyperprolactinemic patients with visual field constriction. Fertil. Steril. 29: 632, 1978.

    PubMed  CAS  Google Scholar 

  16. Wollesen F., Andersen T., Karle A. Size reduction of extrasellar pituitary tumors during bromocriptine treatment. Quantitation of effect on different types of tumors. Ann. Intern. Med. 96: 281, 1982.

    Article  PubMed  CAS  Google Scholar 

  17. Ambrosi B., Travaglini P., Moriondo P., Nissim M., Nava C., Bochicchio D., Faglia G. Effects of bromocriptine and metergoline in the treatment of hyperprolactinemic states. Acta Endocrinol. (Kbh) 100: 10, 1982.

    CAS  Google Scholar 

  18. Spark R.F., Baker R., Bienfang D.C., Bergland R. Bromocriptine reduces pituitary tumor size and hypersecretion. Requiem for pituitary surgery? J. Am. Med. Assoc. 247: 311, 1982.

    Article  CAS  Google Scholar 

  19. Quadri S.K., Lu K.H., Meites J. Ergot-induced inhibition of pituitary tumor growth in rats. Science 176: 417, 1972.

    Article  PubMed  CAS  Google Scholar 

  20. Lloyd H.M., Meares J.D., Jacobi J. Effects of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells. Nature: 255: 497, 1975.

    Article  PubMed  CAS  Google Scholar 

  21. Woodhouse N.J.Y., Khouqueer F., Sieck J.O. Prolactinomas and optic nerve compression: disappearance of a suprasellar extension and visual recovery after two weeks bromocriptine treatment. Horm. Res. 14: 141, 1981.

    Article  PubMed  CAS  Google Scholar 

  22. Thorner M.O., Perryman R.L., Rogol A.D., Convay B.P., MacLeod R.M., Login I.S., Morris J.L. Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J. Clin. Endocrinol. Metab. 153: 480, 1981.

    Article  Google Scholar 

  23. Vezina J.L. Prolactin-secreting pituitary adenomas: radiologic diagnosis. In: Robin C., Harter M. (Eds.), Progress in prolactin physiology and pathology. Elsevier North Holland Biomedical Press, 1978, p. 351.

    Google Scholar 

  24. Roth J., Bendayan M., Orci L. Ultrastructural localization of intracellular antigens by the use of protein A-gold complex. J. Histochem. Cytochem. 26: 1074, 1978.

    Article  PubMed  CAS  Google Scholar 

  25. Genze H.J., Slot J.W., Van der Ley P.A., Scheffer R.C.T., Griffith J.M. Use of colloidal gold-particles in double-labeling immunoelectron microscopy of ultrathin frozen tissue sections. J. Cell Biol. 89: 653, 1981.

    Article  Google Scholar 

  26. Werbel E.R. Stereological principles for morphometry in electron microscopic citology. Int. Rev. Cytol. 26: 235, 1969.

    Article  Google Scholar 

  27. Peilion F., Racadot J., Olivier L., Vila-Porcile E. Microadenomas, structure and function. In: Faglia G., Giovanelli M.A., MacLeod R.M. (Eds.), Pituitary microadenomas. Academic Press, London, 1980, p. 91.

    Google Scholar 

  28. George S.R., Burrow G.N., Zinman B., Ezrin C. Regression of pituitary tumors, a possible effect of bromoergocryptine. Am. J. Med. 66: 697, 1979.

    Article  PubMed  CAS  Google Scholar 

  29. Eversmann T., Fahlbusch R., Ryosk H.K., VonWerder K. Persisting suppression of prolactin secretion after long-term treatment with bromocriptine in patients with prolactinomas. Acta Endocrinol. (Kbh.) 92: 413, 1979.

    CAS  Google Scholar 

  30. Lamberts S.J.W., MacLeod R.M. The inability of bromocriptine to inhibit prolactin secretion by transplantable rat pituitary tumors: observations on the mechanism and dynamics of the autofeedback regulation of prolactin secretion. Endocrinology 104: 65, 1979.

    Article  PubMed  CAS  Google Scholar 

  31. Mc Comb D.J., Kovacs K., Croxford R., Milligan J.V. Bromocriptine suppression of dispersed pituitary lactotrophs from estrogen-pretreated rats: a quantitative electron microscopic study. Can. J. Physiol. Pharmacol. 60: 154, 1982.

    Article  CAS  Google Scholar 

  32. Thorner M.O., Tindall G.T., Kovacs K., Horvath E. Human prolactinomas and bromocriptine: a histologic, immunocytochemical, ultrastructural and morphometric study. The Endocrine Society 64th Annual Meeting — San Francisco, June 16–18, 1982, p. 149 (Abstract 277).

    Google Scholar 

  33. Rengachary S.S., Tomita T., Jefferies B.F., Watanabe I. Structural changes in human pituitary tumor after bromocriptine treatment. Neurosurgery 10: 242, 1982.

    Article  PubMed  CAS  Google Scholar 

  34. Brismar K., Siden A., Werner S. Effects of bromocriptine on CSF proteins and amines in patients with empty sella syndrome, acromegaly and prolactin producing pituitary adenomas. J. Endocrinol. Invest. 4: 393, 1981.

    Article  PubMed  CAS  Google Scholar 

  35. Johnston D.G., McGregor A., Ross W.M., Hall R. Bromocriptine therapy for “non functioning” pituitary tumors. Am. J. Med. 71: 1059, 1981.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cattedra di Endocrinologia e Medicina Costituzionale, Università di Milano, Via Francesco Sforza 35, 20122, Milano, Italia

    M. Nissim, P. Moriondo, A. Spada & G. Faglia

  2. Clinica Medica II, Università di Milano, Via Francesco Sforza 35, 20122, Milano, Italia

    B. Ambrosi & P. Travaglini

  3. Istituto di Neurochirurgia, Università di Milano, Via Francesco Sforza 35, 20122, Milano, Italia

    V. Bernasconi, M. A. Giovanelli & U. Vaccari

  4. Centro CNR per lo Studio della Farmacologia delle Infrastrutture Cellulari — Istituto di Farmacologia, Università di Milano, Via Francesco Sforza 35, 20122, Milano, Italia

    G. Giannattasio & M. Bassetti

Authors
  1. M. Nissim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Ambrosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Bernasconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Giannattasio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. A. Giovanelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Bassetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. U. Vaccari
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P. Moriondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Spada
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P. Travaglini
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G. Faglia
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported in part by a grant from Ministero Pubblica Istruzione, Roma

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nissim, M., Ambrosi, B., Bernasconi, V. et al. Bromocriptine treatment of macroprolactinomas: studies on the time course of tumor shrinkage and morphology. J Endocrinol Invest 5, 409–415 (1982). https://doi.org/10.1007/BF03350542

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03350542

Key-words

Search

Navigation